{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Assessed by Kaplan-Meier survival analysis and 95% confidence intervals will be calculated using Greenwood's formulae.","groups":[{"description":"Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\naflibercept: Given IV","id":"OG000","title":"Treatment (Antiangiogenesis Therapy)"}],"populationDescription":"Data not collected","reportingStatus":"POSTED","timeFrame":"Time from first treatment day until objective or symptomatic progression, assessed up to 6 months","title":"Progression-free Survival (PFS)","type":"SECONDARY"}